Final Program in it's entirety - MyGirlsBlood

Recommendations

Info

Posters, Sunday and Monday Index of Poster Presenters cont’d 07P12 Pharmacokinetic, Efficacy and Safety Data of the First Recombinant Factor VIII from a Human Cell Line Knaub S1 , Jansen M1 , Zozulya N2 , Plyushch O2 1 2 Octapharma AG, Hematology Scientific Center of Russian Academy of Medical Science, Lachen, Russia 07P13 A Prospective, Randomized, and Crossover Study of an Activated Prothrombin Complex Concentrate for Secondary Prophylaxis in Patients with Hemophilia A and Inhibitors (Pro- FEIBA): Subject Demographics and Safety Data Leissinger C1 , Négrier C2 , Berntorp E3 , Windyga J4 , Serban M5 , Bülent A6 , Lassila R7 , Kavakli K8 , Zulfikar B9 , Gringeri A10 1Louisiana Center For Bleeding And Clotting, Tulane University Medical Center, Tulane, France 2Hemophilia Treatment Center, Hôpital Edouard Herriot, University Claude Bernard, Lyon, France, 3Malmö University Hospital, Malmö Centre for Thrombosis and Hemostasis, Malmö, Sweden, 4Institute of Hematology and Transfusion Medicine, Warsaw, Poland, 5Emergency Clinic for Children, Timisoara, Romania, 6 7 Çukurova University, Adana, Turkey, Division of Coagulation Disorders, Helsinki University Central Hospital, Helsinki, Finland, 8University of Ege, Izmir, Turkey, 9Istanbul University, 10 Istanbul, Turkey, Bianchi Bonomi Hemophilia and Thrombosis Center, University of Milan, Milan, Italy 07P14 Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Study of the rFVIIa Variant (BAY 86- 6150) in Hemophilia A or B with or without Inhibitors Mahlangu J1 , Coetzee M2 , Laffan M3 , Windyga J4 , Yee T5 , Schroeder J6 1Hemophilia Comprehensive Care Center, Charlotte Maxeke Johannesburg Academic Hospital And University Of The Witwatersrand, 2Bloemfontein Haemophilia Treatment Centre, University of the Free State, Bloemfontein, South Africa, 3Imperial College, Hammersmith Hospital, London, U.K., 4Institute of Hematology and Transfusion Medicine, Warsaw, Poland, 5The Royal Free Hospital, London, U.K., 6Bayer Schering Pharma AG, Berlin, Germany 07P15 Long-Term Clinical Safety of FEIBA, Activated Prothrombin Complex Concentrate (APCC) in Japanese Inhibitor Subjects: An Update of Post-Authorization Safety Surveillance (PASS) Program Midori S 1 , Kagehiro A2 , Ei K3 , Shinji M4 , Tadashi M5 , Satoshi H6 , Teruhisa F7 , Michio S8 and the FINE study group9 1 2 Nara Medical University, Nara Tokyo Medical University Hospital, 3Ogikubo Hospital, 4St. Marianna University School of Medicine, Kanagawa, 5Nagoya University School of Medicine, Aichi, 6Hyogo College of Medicine, Hyogo, 7 8 Hiroshima University Hospital, Hiroshima, University of Environmental and Occupational Health Japan, Fukuoka, and 9Baxter BioScience Japan, Medical Affairs Clinical Trial, Tokyo, Japan 50 07P16 Long-Acting Glycopegylated Recombinant Activated Factor VII (LA-rFVIIa) is Safe and Shows a Prolonged FVIIa Half-Life after Single and Multiple Administrations in Hemophilia A and B Patients, Making it Suitable for Development as Prophylactic Treatment of Patients with Hemophilia and Inhibitors Møss J1 , Stenmo C1 , Jimenez-Yuste V2 , Bottcher S1 , Fernandez, I2 1 2 Novo Nordisk A/S, Denmark, Hospital Universitario La Paz, Madrid, Spain 07P17 Efficacy, Safety and Immunogenicity of Wilate ® in Children Under 6 Years of Age with Inherited von Willebrand Disease Nowak-Goettl U1 , Kruempel A1 , Russo A2 , Jansen M3 , Knaub S4 1University Hospital, Westfälische Wilhelms-Universität, Münster, Germany, 2University Hospital, Johannes Gutenberg- 3 Universität Mainz, Germany, Octapharma Produk - tionsgesellschaft mbH, Vienna, Austria, 4Octapharma AG, Lachen, Switzerland 07P18 Safety and Efficacy of B-Domain-Deleted Recombinant FVIII – Final Results of a 10-Year Pharmacovigiliance Study Westfeld M1 , Pollmann H2 for the ReFacto ® Phar - macovigilance Data Monitoring Board 1Wyeth Pharma GmbH - ein Unternehmen der Pfizer-Gruppe, 2 Muenster, ITH - Institut für Thrombophilie und Haemostaseologie, Bonn, Germany 07P19 Two-year Interim Results of a Non-Interventional Trial to Assess the Safety and Efficacy of Treatment with Recombinant Factor IX Westfeld M1 , Pollmann H2 , Oldenburg J3 1Wyeth Pharma GmbH - ein Unternehmen der Pfizer-Gruppe, 2 Muenster, ITH - Institut für Thrombophilie und Haemostaseologie, 3Universitaetsklinikum Bonn, Germany 07P20 Clinical Efficacy of a Novel VWF-Containing FVIII Concentrate, Wilate ® , in the Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Hemophilia A Patients Klukowska A1 , Windyga J2 , Batorova A3 1Department of Pediatrics, Hematology and Oncology, Medical University of Warsaw, Warszawa, Poland, 2Department of Hemostasis Disturbances and Internal Diseases, Institute of Hematology and Transfusiology, Warszawa, Poland, 3University Hospital Clinic Haematology & Blood Transfusion, Bratislava, Slovak Republic
Index of Poster Presenters cont’d 07P21 Effectively Platform for Coagulation Recombinant Protein Production by Transgenic Farm Mammals Yang C, Chang Y Animal Technology Institute Taiwan, Republic of China 07P22 Safety and Efficacy of Plasma/Albumin-Free Recombinant Factor VIII for the Treatment of Previously Treated Patients with Hemophilia A in China: A 6 Month Compassionate Use Study Yang R1 , Zhao Y, Sun J, Wang X, Yu M 1Department of Hematology, Institute of Hematology & 2 Blood Diseases Hospital, Tianjin, Department of Hematology, Peking Union Medical College Hospital, Beijing, 3Department of Hematology, Nanfang Hospital, Guangzhou, 4Transfusion Department, Nanfang Hospital, Shanghai, 5Medical Affairs, Baxter China Investment Co Ltd, Beijing, Republic of China 07P23 Intracranial Hemorrhage (ICH) in Hemophilia A and B: An Italian Retrospective Survey Zanon E1 , Rocino A2 , Santagostino E3 , Messina M4 , Pasca S5 , Valdrè E6 1 2 Clinica Medica II Azienda Ospedaliera Di Padova, Centro Emofilia e Trombosi Ospedale S.Giovanni Bosco Napoli, Centro Emofilia e Trombosi Bianchi Bonomi Ospedale Maggiore Milano, 4Centro Emofilia Ospedale Infantile Regina 5 Margherita Torino, Centro Emofilia Istituto ImmunoTrasfusionale Azienda Ospedaliera Maria della Misericordia, 6UO Angiologia e Malattie Coagulazione Bologna, Italy 07P24 Pharmacokinetics of a Recombinant Albumin-Fused, Human Coagulation Factor VIIa (rVIIa-FP) Exhibiting Prolonged Serum Half-Life in Different Animal Species Zollner S, Weimer T, Schmidbauer S, Raquet E, Mueller- Cohrs J, Schulte S CSL Behring GmbH, Marburg, Germany CLOTTING FACTOR CONCENTRATES 08P02 Evaluation of the Emergency Home Doses of Clotting Factor Concentrates in Hemophilia Patients at Hemocentro de Belo Horizonte Barbosa A, Murao M, Cerqueira A, Junior M Hemocentro de Belo Horizonte, Brazil 08P03 Octanate ® with 50% Volume-Reduced Formulation: Meeting the Needs of Individual Patients Belyanskaya L 1 , Putz M 2 , Gruber G 2 , Stadler M 2 , Gerlach B 3 , Martens A 3 , Khair K 4 , Walter O 1 1 Octapharma AG, Lachen, Switzerland, 2 Octapharma Pharmazeutika Produktionsges .m.b.H, Vienna, Austria, 3 Octapharma GmbH, Langenfeld, Germany, 4 Great Ormond Street Hospital for Children NHS Trust, London, U.K. 08P04 Evaluation of QoL in the Treatment of Hemophilia A Patients with Inhibitors Before and After ITI Therapy with Octanate® Vorobyev P1 , Borisenko O1 , Zozulya N2 , Zhulev Y3 , Telnova E4 , Tonoyan A4 1Russian Society for Pharmacoeconomics and Outcomes Research, 2Hematological Scientific Center of Russian Academy of Medical Sciences, 3Russian Hemophilia Society, 4Federal Service on Surveillance in Healthcare and Social Development of Russian Federation, Russia 08P05 Comparable In-Vitro Potency and Efficacy of 40K PEG-rFIX and BeneFIX® in TEG® in Hemophilia B Patient Blood Christiansen M1 + 2 , Sorensen B1 , Viuff D1 , Ostergaard H1 , Segel S1 1 , Lethagen S + 2 1 2 Novo Nordisk A/S, Maaloev, Denmark, Copenhagen University Hospital, Denmark 08P06 GlycoPEGylated Long Acting Factor VIIa and rFVIIa (NOVOSEVEN®) Show Similar Efficacy in Blood from Hemophilia A Patients Using Thromboelastography (TEG®) Christiansen M1,2 , Sorensen B1 , Viuff D1 , Ezban M1 , Andersen S1 1 , Lethagen S + 2 1 2 Novo Nordisk A/S, Maaloev, Denmark, Copenhagen University Hospital, Denmark 08P07 Pharmacokinetics of OPTIVATE ® , A High Purity FVIII and VWF Concentrate in VWD Patients Dash C, Gillanders K, Akanezi C Bio Products Laboratory, Elstree, U.K. 08P08 Suitability of High Purity Factor IX Concentrate (Replenine- VF) for Administration by Continuous Infusion Dash C, Feldman P, Waterhouse S, Gascoigne E Bio Products Laboratory, Eltree, U.K. 51 Posters, Sunday and Monday
Page 1 and 2: Hemophilia Saturday, July 10 - Wedn
Page 3 and 4: Pre-Congress Sessions cont’d 10:3
Page 5 and 6: Pre-Congress Sessions cont’d 15:0
Page 7 and 8: Congress Sessions cont’d S1.6 - M
Page 9 and 10: Congress Sessions cont’d S2.5 - M
Page 11 and 12: Congress Sessions cont’d n Long T
Page 13 and 14: Congress Sessions cont’d M2.4 - M
Page 15 and 16: Congress Sessions cont’d Tuesday,
Page 17 and 18: Congress Sessions cont’d 14:15 -
Page 19 and 20: Congress Sessions cont’d T3.4 - M
Page 21 and 22: Congress Sessions cont’d n Inhibi
Page 23 and 24: Congress Sessions cont’d W2.4 - L
Page 25 and 26: Index of Speakers cont’d Halimeh,
Page 27 and 28: Index of Poster Presenters Sunday a
Page 29 and 30: Index of Poster Presenters cont’d
Page 35: Index of Poster Presenters cont’d

Final Program in it's entirety - MyGirlsBlood

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?